Pancrelipase: An evidence-based review of its use for treating pancreatic exocrine insufficiency

Core Evidence

Volumn 7, Issue , 2012, Pages 77-91

  Nakajima, Kei ^a   Oshida, Haruki ^a   Muneyuki, Toshitaka ^b   Kakei, Masafumi ^b  

^a JOSAI UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic pancreatitis; Extrapancreatic diseases; Pancreatic diabetes; Pancreatic enzyme replacement therapy; Pancreatic exocrine insufficiency; Steatorrhea

Indexed keywords

LIPID; NITROGEN; PANCRELIPASE; PLACEBO;

ADVERSE OUTCOME; ALCOHOL CONSUMPTION; BLOATING; CELIAC DISEASE; CHRONIC PANCREATITIS; COLON DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOCRINE DISEASE; ENTERIC FEEDING; ENZYME REPLACEMENT; EVIDENCE BASED PRACTICE; FIBROSING COLONOPATHY; FOOD AND DRUG ADMINISTRATION; GASTRECTOMY; GASTROINTESTINAL DISEASE; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; IRRITABLE COLON; LIPID ABSORPTION; LOW FAT DIET; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS EXOCRINE INSUFFICIENCY; PANCREAS RESECTION; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; STOMACH PAIN; UNITED STATES; ZOLLINGER ELLISON SYNDROME;

EID: 84873177926     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S26705     Document Type: Review

References (92)

1. Keller J, Aghdassi AA, Lerch MM, Mayerle JV, Layer P. Tests of pancreatic exocrine function-clinical significance in pancreatic and non-pancreatic disorders. Best Pract Res Clin Gastroenterol. 2009;23(3):425-439.
2. Rhodes B, Nash EF, Tullis E, et al. Prevalence of dyslipidemia in adults with cystic fibrosis. J Cyst Fibros. 2010;9(1):24-28.
3. Domínguez Muñoz JE. Diagnosis of chronic pancreatitis: functional testing. Best Pract Res Clin Gastroenterol. 2010;24(3):233-241.
4. Hammer HF. Pancreatic exocrine insufficiency: diagnostic evaluation and replacement therapy with pancreatic enzymes. Dig Dis. 2010; 28(2):339-343.
5. Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011;8(7):405-415.
6. Taylor JR, Gardner TB, Waljee AK, Dimagno MJ, Schoenfeld PS. Systematic review: efficacy and safety of pancreatic enzyme supplements for exocrine pancreatic insufficiency. Aliment Pharmacol Ther. 2010;31(1):57-72.
7. Dhanasekaran R, Toskes PP. Pancrelipase for pancreatic disorders: an update. Drugs Today (Barc). 2010;46(11):855-866.
8. Krishnamurty DM, Rabiee A, Jagannath SB, Andersen DK. Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis. Ther Clin Risk Manag. 2009; 5(3):507-520.
9. Application for the inclusion of pancreatic enzymes in the World Health Organisation Model List of Essential Medicines. Presented at the Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines, 29 September-3 October, Geneva, Switzerland, 2008.
10. Layer P, Keller J. Lipase supplementation therapy: standards, alternatives, and perspectives. Pancreas. 2003;26(1):1-7. (Pubitemid 36020259)
11. Domínguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Gastroenterol Hepatol (N Y). 2011;7(6):401-403.
12. Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol. 2011;26 Suppl 2:12-16.
13. Nunes AC, Pontes JM, Rosa A, Gomes L, Carvalheiro M, Freitas D. Screening for pancreatic exocrine insufficiency in patients with diabetes mellitus. Am J Gastroenterol. 2003;98(12):2672-2675. (Pubitemid 38028556)
14. Hardt PD, Hauenschild A, Jaeger C, et al. High prevalence of steatorrhea in 101 diabetic patients likely to suffer from exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations: a prospective multicenter study. Dig Dis Sci. 2003;48(9):1688-1692. (Pubitemid 37174716)
15. Hardt PD, Ewald N. Exocrine pancreatic insufficiency in diabetes mellitus: a complication of diabetic neuropathy or a different type of diabetes? Exp Diabetes Res. 2011;2011:761950.
16. Rothenbacher D, Löw M, Hardt PD, Klör HU, Ziegler H, Brenner H. Prevalence and determinants of exocrine pancreatic insufficiency among older adults: results of a population-based study. Scand J Gastroenterol. 2005;40(6):697-704. (Pubitemid 40827532)
17. Herzig KH, Purhonen AK, Räsänen KM, et al. Fecal pancreatic elastase-1 levels in older individuals without known gastrointestinal diseases or diabetes mellitus. BMC Geriatr. 2011;11:4.
18. Andersen BN, Pedersen NT, Scheel J, Worning H. Incidence of alcoholic chronic pancreatitis in Copenhagen. Scand J Gastroenterol. 1982;17(2):247-252. (Pubitemid 12185529)
19. Kopelman P. Health risks associated with overweight and obesity. Obes Rev. 2007;8 Suppl 1:13-17.
20. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol. 2010;316(2):104-108.
21. Chowdhury RS, Forsmark CE. Review article: pancreatic function testing. Aliment Pharmacol Ther. 2003;17(6):733-750. (Pubitemid 36418871)
22. Sikkens EC, Cahen DL, Kuipers EJ, Bruno MJ. Pancreatic enzyme replacement therapy in chronic pancreatitis. Best Pract Res Clin Gastroenterol. 2010;24(3):337-347.
23. Lüth S, Teyssen S, Forssmann K, Kölbel C, Krummenauer F, Singer MV. Fecal elastase-1 determination: 'gold standard' of indirect pancreatic function tests? Scand J Gastroenterol. 2001;36(10):1092-1099. (Pubitemid 32801697)
24. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973;288(16):813-815.
25. Lankisch PG, Lembcke B, Wemken G, Creutzfeldt W. Functional reserve capacity of the exocrine pancreas. Digestion. 1986;35(3):175-181. (Pubitemid 16001678)
26. Ammann RW, Muellhaupt B. The natural history of pain in alcoholic chronic pancreatitis. Gastroenterology. 1999;116(5):1132-1140. (Pubitemid 29203023)
27. Imoto M, DiMagno EP. Cigarette smoking increases the risk of pancreatic calcification in late-onset but not early-onset idiopathic chronic pancreatitis. Pancreas. 2000;21(2):115-119. (Pubitemid 30612850)
28. Law R, Parsi M, Lopez R, Zuccaro G, Stevens T. Cigarette smoking is independently associated with chronic pancreatitis. Pancreatology. 2010;10(1):54-59.
29. Nakajima K, Nemoto T, Muneyuki T, Kakei M, Fuchigami H, Munakata H. Low serum amylase in association with metabolic syndrome and diabetes: a community-based study. Cardiovasc Diabetol. 2011;10:34.
30. Mössner J, Keim V. Pancreatic enzyme therapy. Dtsch Arztebl Int. 2010;108(34-35):578-582.
31. Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1679-1688.
32. Safdi M, Bekal PK, Martin S, Saeed ZA, Burton F, Toskes PP. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas. 2006;33(2):156-162. (Pubitemid 44174563)
33. Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gastroenterol. 2010;105(10):2276-2286.
34. Gubergrits N, Malecka-Panas E, Lehman GA, et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther. 2011;33(10):1152-1161.
35. Toskes PP, Secci A, Thieroff-Ekerdt R; ZENPEP Study Group. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis. Pancreas. 2011;40(3):376-382.
36. Giuliano CA, Dehoorne-Smith ML, Kale-Pradhan PB. Pancreatic enzyme products: digesting the changes. Ann Pharmacother. 2011; 45(5):658-666.
37. Nøjgaard C, Bendtsen F, Becker U, Andersen JR, Holst C, Matzen P. Danish patients with chronic pancreatitis have a four-fold higher mortality rate than the Danish population. Clin Gastroenterol Hepatol. 2010;8(4):384-390.
38. Baker SS. Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis. Ther Clin Risk Manag. 2008;4(5):1079-1084.
39. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2002;1(2):51-75.
40. Hayek KM. Medical nutrition therapy for cystic fibrosis: beyond pancreatic enzyme replacement therapy. J Am Diet Assoc. 2006;106(8):1186-1188. (Pubitemid 44079978)
41. Stern RC, Eisenberg JD, Wagener JS, et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol. 2000;95(8):1932-1938.
42. Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2009;8(6):370-377.
43. Colombo C, Fredella C, Russo MC, et al. Efficacy and tolerability of Creon for children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas. 2009;38(6):693-699.
44. Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros. 2009;8(6):405-417.
45. Graff GR, Maguiness K, McNamara J, et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin Ther. 2010;32(1):89-103.
46. Trapnell BC, Strausbaugh SD, Woo MS, et al. Efficacy and safety of Pancreaze® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2011;10(5):350-356.
47. Olveira G, Olveira C. Nutrition, cystic fibrosis and the digestive tract. Nutr Hosp. 2008;23 Suppl 2:71-86. (Pubitemid 351947287)
48. Van Hoozen CM, Peeke PG, Taubeneck M, Frey CF, Halsted CH. Efficacy of enzyme supplementation after surgery for chronic pancreatitis. Pancreas. 1997;14(2):174-180. (Pubitemid 27106105)
49. Ferrie S, Graham C, Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. Nutr Clin Pract. 2011;26(3):349-351.
50. Shlieout G, Koerner A, Maffert M, Forssmann K, Caras S. Administration of Creon® pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study. Clin Drug Investig. 2011;31(7):e1-e7.
51. Davidson GP, Hassel FM, Crozier D, Corey M, Forstner GG. Iatrogenic hyperuricemia in children with cystic fibrosis. J Pediatr. 1978;93(6):976-978. (Pubitemid 9018756)
52. Lloyd-Still JD, Beno DW, Kimura RM. Cystic fibrosis colonopathy. Curr Gastroenterol Rep. 1999;1(3):231-237.
53. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007;27(6):910-920. (Pubitemid 46849433)
54. Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008;108(5):832-839. (Pubitemid 351602057)
55. Prescott P, Bakowski MT. Pathogenesis of fibrosing colonopathy: the role of methacrylic acid copolymer. Pharmacoepidemiol Drug Saf. 1999;8(6):377-384. (Pubitemid 29527859)
56. Lee J, Ip W, Durie P. Is fibrosing colonopathy an immune-mediated disease? Arch Dis Child. 1997;77(1):66-70.
57. Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004;18(5):947-955. (Pubitemid 39378181)
58. Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25(4):452-460. (Pubitemid 32455198)
59. Hardt PD, Brendel MD, Kloer HU, Bretzel RG. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes Care. 2008;31 Suppl 2:S165-S169.
60. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012;28(4):338-342.
61. Ito T, Otsuki M, Igarashi H, et al. Epidemiological study of pancreatic diabetes in Japan in 2005: a nationwide study. Pancreas. 2010;39(6):829-835.
62. Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011;11(3):279-294.
63. Eliasson B, Attvall S, Taskinen MR, Smith U. The insulin resistance syndrome in smokers is related to smoking habits. Arterioscler Thromb. 1994;14(12):1946-1950.
64. Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008;87(4):801-809. (Pubitemid 351549222)
65. Rashtak S, Murray JA. Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther. February 13, 2012. [Epub ahead of print.]
66. Fine KD, Meyer RL, Lee EL. The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet. Gastroenterology. 1997;112(6):1830-1838. (Pubitemid 27240767)
67. Kurppa K, Collin P, Mäki M, Kaukinen K. Celiac disease and health-related quality of life. Expert Rev Gastroenterol Hepatol. 2011;5(1):83-90.
68. Fasano A, Berti I, Geraduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States. Arch Intern Med. 2003;163(3):286-292. (Pubitemid 36183856)
69. Green PH, Jabri B. Coeliac disease. Lancet. 2003;362(9381):383-391. (Pubitemid 36945070)
70. Evans KE, Leeds JS, Morley S, Sanders DS. Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation? Dig Dis Sci. 2010;55(10):2999-3004.
71. Carroccio A, Iacono G, Montalto G, et al. Pancreatic insufficiency in celiac disease is not dependent on nutritional status. Dig Dis Sci. 1994; 39(10):2235-2242. (Pubitemid 24341640)
72. Leeds JS, Hopper AD, Hurlstone DP, et al. Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? Aliment Pharmacol Ther. 2007;25(3):265-271. (Pubitemid 46115396)
73. Kellow JE. IBS: do we need to exclude exocrine pancreatic insufficiency in IBS? Nat Rev Gastroenterol Hepatol. 2010;7(9):479-480.
74. Leeds JS, Hopper AD, Sidhu R, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010;8(5):433-438.
75. Pitchumoni CS, Rubin A, Das K. Pancreatitis in inflammatory bowel diseases. J Clin Gastroenterol. 2010;44(4):246-253.
76. Angelini G, Cavallini G, Bovo P, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3(2-3):185-193. (Pubitemid 18078931)
77. Maconi G, Dominici R, Molteni M, et al. Prevalence of pancreatic insufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. Dig Dis Sci. 2008;53(1):262-270. (Pubitemid 350265679)
78. Seyrig JA, Jian R, Modigliani R, et al. Idiopathic pancreatitis associated with inflammatory bowel disease. Dig Dis Sci. 1985;30(12):1121-1126. (Pubitemid 16132369)
79. Nieto JM, Pisegna Jr. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2006;7(2):169-175. (Pubitemid 43263256)
80. Tomassetti P, Campana D, Piscitelli L, et al. Treatment of Zollinger-Ellison syndrome. World J Gastroenterol. 2005;11(35):5423-5432. (Pubitemid 41684697)
81. Friess H, Böhm J, Ebert M, Büchler M. Enzyme treatment after gastrointestinal surgery. Digestion. 1993;54 Suppl 2:48-53. (Pubitemid 23247555)
82. Domínguez-Muñoz JE. Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery. HPB (Oxford). 2009;11 Suppl 3:3-6.
83. Williams JA, Goldfine ID. The insulin-pancreatic acinar axis. Diabetes. 1985;34(10):980-986. (Pubitemid 16236516)
84. Mössner J, Logsdon CD, Goldfine ID, Williams JA. Regulation of pancreatic acinar cell insulin receptors by insulin. Am J Physiol. 1984;247(2 Pt 1):G155-G160. (Pubitemid 14063084)
85. Ewald N, Bretzel RG, Fantus IG, et al. Pancreatin therapy in patients with insulin-treated diabetes mellitus and exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations. Results of a prospective multi-centre trial. Diabetes Metab Res Rev. 2007;23(5):386-391. (Pubitemid 47091242)
86. Knop FK, Vilsbøll T, Larsen S, et al. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab. 2007;292(1):E324-E330. (Pubitemid 46052957)
87. Laugier R, Bernard J, Berthezene P, Dupuy P. Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly. Digestion. 1991;50:202-211.
88. Vellas B, Balas D, Moreau J, et al. Exocrine pancreatic secretion in the elderly. Int J Pancreatol. 1988;3(6):497-502. (Pubitemid 19046345)
89. Angelirni G, Merigo F, Degani G, et al. Association of chronic alcoholic liver and pancreatic disease: a prospective study. Am J Gastroenterol. 1985;80(12):998-1003. (Pubitemid 16172405)
90. Hayakawa T, Kondo T, Shibata T, et al. Exocrine pancreatic function in chronic liver diseases. Am J Gastroenterol. 1991;86(2):201-204.
91. Ventrucci M, Campieri C, Di Stefano M, et al. Alterations of exocrine pancreas in end-stage renal disease. Do they reflect a clinically relevant uremic pancreopathy? Dig Dis Sci. 1995;40(12):2576-2581. (Pubitemid 26032348)
92. Griesche-Philippi J, Otto J, Schwörer H, Maisonneuve P, Lankisch PG. Exocrine pancreatic function in patients with end-stage renal disease. Clin Nephrol. 2010;74(6):457-464.